drugset / Trial / NCT03192657
Basiliximab Treating Interstitial Pneumonia of CADM
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a 52-week, randomized, open and routine treatment controlled study. This study will assess the safety and efficacy of basiliximab as an add-on treatment for interstitial pneumonia in clinical amyopathic dermatomyositis (CADM) patients. 100 CADM patients are planned to be enrolled in a single center.
Timeline
- Start
- 2017-07
- Primary completion
- 2019-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | — |
| Background | Cyclosporine | Peptide | 5 mg/kg | — |
| Background | Prednisone | Other / unclassified | 1 mg/kg | — |
| Background | Tacrolimus | Small molecule | 0.05 mg/kg | — |
| Background | Tacrolimus | Small molecule | 0.1 mg/kg | — |